📈 Top Insider Buys April 2026: PRLD, THM, TORO, SMPL & More

Officers and Directors Are Buying the Dip — Here’s What the Smart-Money Receipts Say

Insider Watchlist Snapshot — Prices as of Apr-24-2026 close
NASDAQ: PRLD — $4.70 | NYSE: THM — $2.63 | NASDAQ: TORO — $6.90 | NASDAQ: RZLV — $2.62 | NYSE: HOMB — $26.46 | NASDAQ: SMPL — $13.36 | NYSE: BMI — $121.83 | NASDAQ: OKTA — $75.99

🧠 FUNanc1al Atomic Statements

1️⃣ “An insider buy is not a prophecy; it’s a receipt.”

2️⃣ “The best insider signals are large, repeated, clustered—and still not magic.”

3️⃣ “When executives buy with real money, Wall Street commentary becomes a little less theoretical.”

At FUNanc1al, we love analyst opinions.

They are colorful.
They are confident.
They are often delivered by people who are not wiring large chunks of their own money into a falling stock.

Insiders, on the other hand?

They have skin in the game, stock in the game, and occasionally yacht money in the game. 🛥️

When a CEO, director, or 10% owner reaches into their own pocket and hits BUY in size, that is not commentary.

👉 That is discomfort.
👉 That is conviction.
👉 That is a signal worth watching.

So here is the Week 3 April 2026 insider scoreboard — a select list across biotech, mining, shipping, AI, banking, snacks, water infrastructure, and cybersecurity.

The theme?

👉 The Rerate Trade.

Insiders are buying beaten-down names, turnaround narratives, and value stories where the market has basically said: “Show me.” They are responding: “Fine. Here’s my checkbook.”

🏆 1) Prelude Therapeutics — PRLD

NASDAQ: PRLD — $4.70 (+0.30, +6.82%) As of Apr-24-2026 4:00 PM ET

This is not a “symbolic alignment” buy.

This is a load-the-truck biotech moment.

Prelude saw two massive insider/10% owner purchases at $4.44, each around $12.5 million, following earlier CEO buying at much lower prices. That matters because clinical-stage biotech often lives in the land of hope, dilution, and PowerPoint molecules.

Prelude is developing precision oncology medicines, including programs targeting JAK2V617F and KAT6A. The company also recently priced an underwritten offering of about 18 million shares at $4.44, expected to raise roughly $90 million—classic biotech fuel, but also classic dilution. Its PRT13722 KAT6A degrader program remains on track for an IND filing around mid-2026, with clinical trial initiation planned later in 2026, according to company-related reporting.

FUNanc1al Take:
PRLD has promise, smart biotech money around it, and low-ish short interest for a small biotech. But this remains a clinical-stage name. No product revenue miracle yet. No free lunch. Just science, dilution, risk, and optionality wearing a lab coat. 🧬

🍟 2) International Tower Hill Mines — THM

NYSE: THM — $2.63 (+0.10, +3.95%) As of Apr-24-2026 4:10 PM ET

THM is the “gold mine with a tweak” name, and yes, Paulson keeps showing up.

That alone does not make it safe.

But repeat buying by a high-profile investor in a hard-asset story during a volatile macro environment deserves attention. Gold, antimony optionality, strategic minerals, and geopolitical weirdness all sit in the same cocktail glass here.

FUNanc1al Take:
THM may be one of the week’s most interesting macro-meets-mining insider setups. But mining stories can take years, permits can punch you in the face, and geology does not care about your timeline.

For our full take on International Tower Hill Mines, check this out. 

🚢 3) Toro Corp. — TORO

NASDAQ: TORO — $6.90 (+0.23, +3.45%) As of Apr-24-2026 4:00 PM ET

Toro’s CEO Petros Panagiotidis bought more than $14 million worth of stock.

That is serious.

Toro is a Cyprus-based shipping company focused on LPG carriers and tankers. Insiders own a huge portion of the company, but institutional ownership is tiny. Translation: the captain owns a lot of the ship, but the big asset allocators are still standing on the dock with binoculars.

Toro reported $1.6 million of Q4 2025 net income and $5.9 million of full-year 2025 net income, down from $25.2 million in 2024, with the decline tied to restructuring and the spin-off of its Handysize tanker segment.

FUNanc1al Take:
Huge CEO buy? Bullish signal.
Governance and microcap shipping complexity? Giant yellow flag.
Proceed with a life vest. 🛟

🤖 4) Rezolve AI — RZLV

NASDAQ: RZLV — $2.62 (+0.02, +0.77%) As of Apr-24-2026 4:00 PM ET

Rezolve AI is the spicy one.

CEO Daniel Wagner bought 812,956 shares at $4.00, despite the stock trading lower afterward.

That is conviction. But RZLV also has high short interest, low institutional sponsorship, steep losses, and a valuation that depends on a very aggressive growth ramp.

In other words:

🚀 Bulls see AI retail disruption.
🐻 Bears see cash burn with a chatbot costume.

FUNanc1al Take:
This is not a “buy and nap” stock. This is a “watch the burn rate and keep smelling salts nearby” stock.

🏦 5) Home BancShares — HOMB

NYSE: HOMB — $26.46 As of Apr-24-2026 4:10 PM ET

CEO John W. Allison bought about $2.7 million worth of HOMB stock.

Bank CEOs buying size can be meaningful because they live inside the credit machine. They see loan demand, deposit behavior, credit quality, and the stuff that makes bank analysts either smile or chew pencils.

FUNanc1al Take:
A serious CEO buy in a quality regional bank is worth watching—especially if rate expectations, credit risk, and valuation start aligning.

For our full take on Home Bancshares, check this out. 

🍫 6) Simply Good Foods — SMPL

NASDAQ: SMPL — $13.36 As of Apr-24-2026 4:00 PM ET

Director James Kilts bought roughly $991,000 worth of SMPL stock at $12.39.

This one is tasty.

SMPL has Quest, Atkins, and OWYN—but also margin pressure, Atkins weakness, and a turnaround that may need more protein powder than optimism.

FUNanc1al Take:
Cheap valuation + respected consumer veteran + insider buy = interesting.
Weak growth + margin pressure = still not dessert.

For our full take on Simply Good Foods, check this out. 

💧 7) Badger Meter — BMI

NYSE: BMI — $121.83 As of Apr-24-2026 close

BMI had a cluster of insider purchases from multiple executives.

That matters because clustered buying often beats lonely buying. One executive can be optimistic. Several executives buying after a selloff starts to look more like internal alignment.

FUNanc1al Take:
Water infrastructure is not sexy, but neither is plumbing—until it breaks. BMI remains a quality name where insider buying after a pullback deserves attention.

For our full take on Badger Meter, check this out. 

🛡️ 8) Okta — OKTA

NASDAQ: OKTA — $75.99 (+0.01, +0.01%)

Director David Schellhase bought about $267,000 worth of OKTA.

Okta sits at the intersection of identity security, enterprise software, and AI-driven risk. Not a huge purchase relative to some names on this list, but notable because cybersecurity identity remains a long-term battlefield.

FUNanc1al Take:
Smaller signal, better-quality company. Sometimes the most boring insider buys are the least chaotic. 

For our full take on Okta, check this out. 

⚡ Quick Take / TL;DR

🏆 Biggest “Wow” Buy: PRLD
🍟 Best Macro/Hard-Asset Setup: THM
🚢 Highest Conviction / Highest Weirdness: TORO
🤖 Most Speculative AI Bet: RZLV
🏦 Best CEO Confidence Signal: HOMB
🍫 Best Consumer Turnaround Snack: SMPL
💧 Best Cluster Buy: BMI
🛡️ Best Quality-Tech Signal: OKTA

👉 Insider buying matters most when it is:

Large.
Repeated.
Clustered.
Open-market.
And backed by a plausible business catalyst.

📌 Signal Extract:

“An insider buy is not a prophecy; it’s a receipt.”

🎯 High-Conviction Takeaway:

“The best insider signals are large, repeated, clustered—and still not magic.”

❓ FAQ

Are insider buys always bullish?
No. They are helpful signals, not guarantees. Some insiders buy early. Some buy wrong. Some average down into disasters.

What type of insider buy matters most?
Large open-market purchases by CEOs, CFOs, directors, founders, or 10% owners.

Why does PRLD stand out?
Size, biotech optionality, institutional biotech holders, and fresh pipeline catalysts.

Why be cautious on TORO and RZLV?
TORO has governance/microcap shipping complexity. RZLV has high losses, high short interest, and execution risk.

Should investors blindly copy insiders?
Absolutely not. Follow the signal, then do the homework.

🧠 Food for Thought: The Cross-Hub Connection

Insider buying is like ordering at a great restaurant. 🍽️

The menu = analyst reports.
The chef’s special = insider buying.

Both matter.

But only one involves real money placed on the table.

And in markets, as in life:

👉 Talk is cheap.
👉 Receipts matter.
👉 Dessert is optional. Risk management is not.

✍️ About the Author

Frédéric Marsanne is the founder of FUNanc1al — part market analyst, part storyteller, part accidental comedian. A longtime investor, entrepreneur, and venture-builder across tech, biotech, and fintech, he now blends sharp insights with a twist of humor to help readers laugh, learn, live better lives, and invest a little wiser. When not decoding insider buys or poking fun at earnings calls, he’s building Cl1Q, writing fiction, painting, or discovering new passions to FUNalize.

🧾⚠️📢 Fun(anc1al) but Serious Disclaimer: 🧾⚠️📢

This is not financial advice. Insider buys are useful signals, not guaranteed jackpots. Some insiders are brilliant. Some are early. Some are wrong. And some companies with heavy insider buying still manage to light shareholder value on fire.

This article is for educational and entertainment purposes only and does not constitute financial, investment, legal, tax, medical, or emotional-support advice. Stocks go down. Sometimes a lot. Sometimes for good reasons.

Always do your own research, mind dilution and debt, know your risk tolerance, never confuse “interesting” with “safe,” and consult a licensed financial professional if needed.

We analyze.
We laugh.
We invest carefully.

👉 We’re FUNanc1al — not advisors. 😄📉📈

Invest at your own risk. 🎢📉
Love at any pace. Laugh at every turn. 😄

Be Happy. 😄😄

🧭 Looking for a Different Angle?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny